1. Home
  2. URG vs ADCT Comparison

URG vs ADCT Comparison

Compare URG & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ur Energy Inc (Canada)

URG

Ur Energy Inc (Canada)

HOLD

Current Price

$1.40

Market Cap

477.8M

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$3.80

Market Cap

496.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
URG
ADCT
Founded
2004
2011
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
477.8M
496.7M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
URG
ADCT
Price
$1.40
$3.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$2.52
$7.60
AVG Volume (30 Days)
11.3M
1.7M
Earning Date
11-03-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$39,411,000.00
$75,209,000.00
Revenue This Year
N/A
$10.36
Revenue Next Year
$183.54
$3.87
P/E Ratio
N/A
N/A
Revenue Growth
138.94
6.35
52 Week Low
$0.55
$1.05
52 Week High
$2.35
$4.80

Technical Indicators

Market Signals
Indicator
URG
ADCT
Relative Strength Index (RSI) 53.62 45.88
Support Level $1.28 $3.15
Resistance Level $1.48 $4.28
Average True Range (ATR) 0.08 0.41
MACD 0.01 -0.01
Stochastic Oscillator 70.97 49.70

Price Performance

Historical Comparison
URG
ADCT

About URG Ur Energy Inc (Canada)

Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: